RTI uses cookies to offer you the best experience online. By clicking “accept” on this website, you opt in and you agree to the use of cookies. If you would like to know more about how RTI uses cookies and how to manage them please view our Privacy Policy here. You can “opt out” or change your mind by visiting: http://optout.aboutads.info/. Click “accept” to agree.
Genetic predisposition to adverse neurodevelopmental outcome of extremely low birth weight infants
Varner, M. W., Thom, E. A., Cotten, C. M., Hintz, S. R., Page, G. P., Rouse, D. J., Mercer, B. M., Costantine, M. M., Sorokin, Y., Thorp, J. M., Ramin, S. M., Carpenter, M. W., O'Sullivan, M. J., Peaceman, A. M., Saade, G. R., Dudley, D. J., Caritis, S. N., & Eunice Kennedy Shriver National Institute of Child Health Human Development Maternal-Fetal Medicine Units Network Neonatal Research Network (2024). Genetic predisposition to adverse neurodevelopmental outcome of extremely low birth weight infants. American Journal of Perinatology, 41(S 01), e2710-e2716. https://doi.org/10.1055/s-0043-1774312
Objective This study aimed to evaluate whether there are genetic variants associated with adverse neurodevelopmental outcomes in extremely low birth weight (ELBW) infants.Study Design We conducted a candidate gene association study in two well-defined cohorts of ELBW infants (<1,000 g). One cohort was for discovery and the other for replication. The discovery case-control analysis utilized anonymized DNA samples and evaluated 1,614 single-nucleotide polymorphisms ( SNPs) in 145 genes concentrated in inflammation, angiogenesis, brain development, and oxidation pathways. Cases were children who died by age one or who were diagnosed with cerebral palsy (CP) or neurodevelopmental delay ( Bayley II mental developmental index [MDI] or psychomotor developmental index [PDI]< 70) by 18 to 22 months. Controls were survivors with normal neurodevelopment. We assessed significant epidemiological variables and SNPs associated with the combined outcome of CP or death, CP, mental delay (MDI< 70) and motor delay (PDI< 70). Multivariable analyses adjusted for gestational age at birth, small for gestational age, sex, antenatal corticosteroids, multiple gestation, racial admixture, and multiple comparisons. SNPs associated with adverse neurodevelopmental outcomes with p< 0.01 were selected for validation in the replication cohort. Successful replication was defined as p< 0.05 in the replication cohort.Results Of 1,013 infants analyzed (452 cases, 561 controls) in the discovery cohort, 917 were successfully genotyped for >90% of SNPs and passed quality metrics. After adjusting for covariates, 26 SNPs with p< 0.01 for one ormore outcomes were selected for replication cohort validation, which included 362 infants (170 cases and 192 controls). A variant in SERPINE1, which encodes plasminogen activator inhibitor (PAI1), was associated with the combined outcome of CP or death in the discovery analysis (p = 4.1 x 10(-4)) and was significantly associated with CP or death in the replication cohort (adjusted odd ratio: 0.4; 95% confidence interval: 0.2-1.0; p = 0.039).Conclusion A genetic variant in SERPINE1, involved in inflammation and coagulation, is associated with CP or death among ELBW infants.
